Diethylstilbestrol for Dogs: Uses, Safety, and Veterinary Science
Learn how diethylstilbestrol (DES) is used in canine medicine, its mechanism of action, safety profile, dosing guidelines, and when veterinarians prescribe it for dogs.
What Is Diethylstilbestrol and Why Do Veterinarians Prescribe It for Dogs?
Diethylstilbestrol is a non-steroidal synthetic estrogen first synthesized in 1938. Unlike natural estrogens produced by the ovaries, DES is manufactured chemically and binds to estrogen receptors throughout the body with high affinity. In human medicine, DES was widely prescribed from the 1940s through the 1970s before being linked to severe reproductive cancers in offspring — leading to its near-total withdrawal from human use.
In veterinary medicine, DES found a narrower but enduring role: managing urethral sphincter mechanism incompetence (USMI), commonly called spay-associated incontinence. This condition affects an estimated 5–20% of spayed female dogs, particularly medium-to-large breeds. When the ovaries are removed during spaying, circulating estrogen drops dramatically. Estrogen plays a role in maintaining the tone and vascularization of the urethral mucosa and the responsiveness of the urethral sphincter muscle. Without it, some dogs lose the ability to fully close the urethra, resulting in involuntary urine leakage — most often noticed as damp spots where the dog has been sleeping.
DES was historically the first-line hormonal treatment for USMI. Today, most veterinarians prefer phenylpropanolamine (PPA, brand name Proin®) or estriol (Incurin®) as initial therapies due to their more favorable safety profiles. DES is typically reserved for cases that don't respond adequately to these alternatives.
The Physiological Mechanism: How DES Works in the Canine Body
Estrogen and the Urethral Sphincter
The canine urethra relies on a complex interplay of smooth muscle, striated muscle, vascular tissue, and connective tissue to maintain closure pressure above bladder pressure. Estrogen contributes to this system in several measurable ways:
- Alpha-adrenergic receptor upregulation: Estrogen increases the density and sensitivity of alpha-adrenergic receptors in the urethral smooth muscle, making it more responsive to sympathetic nervous system signals that promote closure.
- Mucosal engorgement: Estrogen promotes blood flow to the submucosal vascular plexus of the urethra. This engorgement acts like a cushion or seal — similar to how nasal tissue swells during congestion — contributing up to 30% of total urethral closure pressure.
- Collagen synthesis: Estrogen supports collagen production in periurethral connective tissue, maintaining structural integrity.
- Epithelial maturation: Estrogen promotes thickening and maturation of the urethral epithelium, improving the mucosal seal.
When DES binds to estrogen receptors (ER-alpha and ER-beta) in these tissues, it mimics the effects of natural estradiol, restoring some of the functional capacity lost after ovariectomy.
The mechanism matters because it explains both the efficacy and the risks. DES doesn't act locally on the urethra alone — it circulates systemically and binds to estrogen receptors in bone marrow, liver, mammary tissue, and the reproductive tract. This systemic distribution is what creates the potential for serious adverse effects.
Dosing, Administration, and What to Expect at the Vet
If your veterinarian determines that DES is appropriate for your dog, the typical protocol follows a loading-and-maintenance pattern. Exact dosing is always determined by your veterinarian based on your dog's weight, health status, and response to therapy.
| Phase | Dose Range | Frequency | Duration |
|---|---|---|---|
| Loading Phase | 0.1–1.0 mg per dog (not per kg) | Once daily | 5–7 days |
| Maintenance Phase | 0.1–1.0 mg per dog | Once weekly (or lowest effective frequency) | Ongoing, with regular vet review |
| Maximum Weekly Dose | Generally not to exceed 2 mg/week total | — | Higher doses increase bone marrow risk |
The goal is always to find the lowest effective dose at the longest possible interval. Some dogs maintain continence on 0.1 mg once weekly; others require higher doses or more frequent administration. Your veterinarian will titrate based on clinical response.
Monitoring Requirements
Because of the risk of bone marrow suppression, dogs on DES require regular blood monitoring:
- Baseline CBC (complete blood count): Before starting DES
- Follow-up CBC: At 1 month, 3 months, and then every 6 months while on therapy
- Watch for: Declining red blood cells, white blood cells, or platelets
Expect to spend approximately $80–$150 per CBC at a general practice veterinary clinic. Factor this monitoring cost into your decision alongside the medication cost itself, which is typically $15–$40 per month for DES tablets depending on dose and pharmacy.
Common Misconceptions About DES in Dogs
| Myth | Fact |
|---|---|
| "DES is completely banned and unavailable." | DES is still available through compounding pharmacies for veterinary use in the United States. It is not commercially manufactured as a finished animal drug product, but compounding pharmacies can prepare it with a valid veterinary prescription. |
| "Any estrogen will fix incontinence." | Not all estrogens are interchangeable. Estriol (Incurin®) is a weaker, shorter-acting estrogen with a safer profile specifically approved for canine USMI. DES is a much more potent synthetic estrogen with different receptor binding kinetics and higher risk. |
| "DES causes cancer in dogs the way it did in humans." | The primary human concern with DES was transplacental exposure — daughters of women who took DES during pregnancy developed vaginal clear cell adenocarcinoma. In dogs, DES is given to adult spayed females, not during pregnancy. The primary concern in dogs is bone marrow toxicity, not reproductive tract cancer. However, estrogen-responsive tumors (mammary) remain a theoretical risk with long-term use. |
| "If my dog leaks urine, she needs DES." | Urinary incontinence has many causes — urinary tract infection, ectopic ureters, bladder stones, neurologic disease, and cognitive decline in senior dogs. A full veterinary workup including urinalysis, urine culture, and possibly imaging is essential before starting any incontinence medication. |
Evolutionary Context: Why Spay-Associated Incontinence Exists
In wild canids — wolves, coyotes, and wild dogs — females retain their ovaries throughout life. The estrous cycle, occurring typically once or twice yearly, provides cyclical surges of estrogen and progesterone that maintain reproductive tract tone, including the urethral sphincter. Ovariectomy (spaying) is an entirely human-created intervention with no natural analog.
From an evolutionary perspective, there was never selective pressure for canids to maintain continence without gonadal hormones because that situation never occurred in nature. The urethral sphincter mechanism evolved to function within a hormonal milieu that includes estrogen. When we remove the source of that estrogen, we create a physiological gap that some dogs' bodies cannot compensate for through remaining mechanisms (sympathetic tone, somatic nerve control, anatomical factors alone).
This explains why not all spayed dogs develop incontinence — individual variation in urethral length, sphincter muscle mass, body condition, and residual adrenal estrogen production all contribute. Studies suggest that larger breeds with shorter urethra-to-body-size ratios are disproportionately affected, supporting the idea that anatomical reserve capacity determines whether the loss of estrogen tips the balance toward leakage.
Breed predisposition data reinforces this evolutionary framing. Research published in veterinary journals has identified Doberman Pinschers, Old English Sheepdogs, Rottweilers, German Shepherds, and Weimaraners among breeds with higher USMI incidence. These are predominantly large, deep-chested breeds where urethral length relative to body mass may be a limiting factor.
Safety Profile, Side Effects, and When DES Signals a Problem
The most serious adverse effect of DES in dogs is bone marrow suppression, which can manifest as:
- Aplastic anemia: Failure of the bone marrow to produce red blood cells, white blood cells, and platelets simultaneously (pancytopenia). This is dose-dependent and can be fatal.
- Thrombocytopenia: Low platelet count, leading to bruising, prolonged bleeding, and petechiae (pinpoint hemorrhages on gums or skin).
- Leukopenia: Low white blood cell count, increasing susceptibility to infections.
Other documented side effects include:
- Vulvar swelling or discharge
- Mammary gland enlargement
- Attraction of male dogs (due to estrogen-related pheromone changes)
- Behavioral changes — some owners report increased irritability or clinginess
- Hepatic enzyme elevation with long-term use
- Increased risk of pyometra-like changes in the uterine stump if tissue remains post-spay
When to Call Your Veterinarian Immediately
If your dog is on DES and you observe any of the following, contact your vet or an emergency clinic right away:
- Pale or white gums (indicates anemia)
- Unexplained bruising or bleeding (nosebleeds, blood in urine or stool)
- Lethargy or collapse
- Fever above 103.5°F (39.7°C)
- Repeated infections or slow wound healing
- Vomiting or refusal to eat lasting more than 24 hours
These may indicate bone marrow toxicity, which can progress rapidly. Early detection through CBC monitoring is critical — by the time clinical signs appear, pancytopenia may already be severe.
How DES Compares to Alternative Treatments for Canine Incontinence
| Treatment | Mechanism | Reported Efficacy | Key Risks | Monthly Cost (approx.) |
|---|---|---|---|---|
| Phenylpropanolamine (Proin®) | Alpha-adrenergic agonist; directly stimulates urethral sphincter contraction | 74–91% of dogs achieve continence | Hypertension, restlessness, tachycardia; caution with heart disease or glaucoma | $25–$60 |
| Estriol (Incurin®) | Short-acting natural estrogen; restores urethral mucosal tone and alpha-receptor sensitivity | ~83% of dogs respond; FDA-approved for canine USMI | Mammary changes, vulvar swelling; lower bone marrow risk than DES due to short half-life | $30–$50 |
| Diethylstilbestrol (DES) | Potent synthetic estrogen; systemic estrogen receptor agonism | ~65–85% of dogs respond (varies by study) | Bone marrow suppression (potentially fatal), hepatic effects, mammary changes | $15–$40 + CBC monitoring ($80–$150 per test) |
| Combination Therapy (PPA + Estrogen) | Targets both alpha-adrenergic and estrogenic pathways | Higher response rate than either alone; used for refractory cases | Cumulative side effects of both medications | $50–$100+ |
| Urethral Bulking Agents (collagen injections) | Physical augmentation of urethral mucosa via cystoscopic injection | Variable; temporary (months), may require repeat procedures | Requires general anesthesia, procedural cost, risk of UTI | $800–$2,000 per procedure |
| Colposuspension Surgery | Surgical repositioning of bladder neck to increase intra-abdominal pressure on urethra | ~50–60% long-term success as sole treatment; higher combined with medication | Invasive surgery, anesthesia risk, may not eliminate need for medication | $1,500–$3,500+ |
This comparison illustrates why DES has moved to second- or third-line status. Phenylpropanolamine and estriol offer comparable efficacy with substantially lower risk profiles. According to the Merck Veterinary Manual, estrogen compounds remain useful in refractory cases, but the availability of safer alternatives has reduced DES utilization significantly since the early 2000s.
Practical Implications for Dog Owners
What This Means for Your Daily Life
- Don't self-diagnose incontinence. Urine leakage can signal UTI, diabetes, kidney disease, Cushing's disease, or neurologic problems. A urinalysis ($45–$80) and urine culture ($35–$60) should always precede incontinence medication.
- Ask about first-line options first. Before requesting DES, discuss Proin® (phenylpropanolamine) or Incurin® (estriol) with your veterinarian. These are appropriate starting points for most dogs with confirmed USMI.
- Budget for monitoring. If DES is prescribed, the medication itself is inexpensive, but mandatory CBC monitoring adds $160–$600 annually (2–4 blood draws per year at $80–$150 each).
- Manage the environment while treatment takes effect. It may take 5–14 days on the loading dose to see improvement. Use waterproof bed covers, increase potty breaks, and consider dog diapers for overnight management. Belly bands work for male dogs with incontinence.
- Never use human DES prescriptions. Human DES formulations (if obtainable) are dosed entirely differently and may contain inactive ingredients unsafe for dogs. Only use medication compounded or dispensed specifically for your dog by a licensed veterinarian or veterinary pharmacy.
- Watch for the male dog problem. Estrogen therapy can make spayed females attractive to intact male dogs due to estrogen-related scent changes. This is a safety concern at dog parks and on walks — keep your dog leashed and supervised.
- Maintain a symptom diary. Track frequency and volume of leakage episodes, time of day (nocturnal vs. daytime), and any triggers (excitement, sleeping position). This data helps your veterinarian assess treatment efficacy and adjust dosing.
Is Urinary Incontinence Normal, and When Does It Signal a Deeper Problem?
Involuntary urine leakage is common but not normal. While USMI affects a significant percentage of spayed females, it is a treatable medical condition, not an inevitable consequence of aging or spaying. Any new onset of incontinence warrants veterinary investigation because:
- Urinary tract infections are present in up to 30% of dogs presenting with incontinence — and may be the sole cause or a complicating factor alongside USMI.
- Ectopic ureters (a congenital condition where ureters bypass the bladder) can present as lifelong incontinence and are most commonly diagnosed in young female dogs, particularly Siberian Huskies, Labrador Retrievers, and Golden Retrievers.
- Spinal cord disease — including intervertebral disc disease (IVDD) or degenerative myelopathy — can disrupt neurologic control of the bladder, presenting as incontinence that may be accompanied by hind limb weakness.
- Cognitive dysfunction syndrome in senior dogs can cause house-training regression that mimics incontinence but has a behavioral/neurologic origin rather than a sphincter failure.
The distinction matters because DES or any incontinence medication will not address these underlying conditions and may delay critical diagnosis. According to the American Veterinary Medical Association, any change in urinary habits should prompt a veterinary visit.
How Is Estrogen Processing in Dogs Different from Humans?
Dogs metabolize estrogens differently than humans in several clinically significant ways:
- Hepatic metabolism: Dogs primarily metabolize estrogens through hepatic conjugation pathways (glucuronidation and sulfation), but their glucuronidation capacity is lower than humans'. This is the same metabolic limitation that makes NSAIDs like ibuprofen more toxic to dogs — slower conjugation means longer circulation time and greater tissue exposure per dose.
- Enterohepatic recirculation: Dogs exhibit significant enterohepatic recirculation of estrogen metabolites, meaning metabolites excreted into bile can be reabsorbed from the intestine, extending the effective duration of action.
- Estrous cycle differences: Female dogs experience a single prolonged estrus (2–3 weeks) with a massive estrogen peak followed by an extended progesterone-dominant diestrus (2–3 months). This is fundamentally different from the human menstrual cycle's relatively modest estrogen fluctuations. The canine system evolved for dramatic hormonal swings, which may partly explain why dogs tolerate short-term high-dose estrogen therapy (like the DES loading phase) reasonably well — but chronic exposure remains problematic.
- Bone marrow sensitivity: Canine bone marrow appears particularly sensitive to exogenous estrogen toxicity compared to many species. This is a well-documented species-specific vulnerability that makes DES riskier in dogs than equivalent compounds would be in other mammals. The mechanism involves direct estrogen-mediated suppression of hematopoietic stem cell proliferation.
Frequently Asked Questions
Can dogs take DES that was prescribed for a human?
No. Human DES formulations are dosed in micrograms to milligrams for entirely different indications and may contain excipients (fillers, binders, coatings) that are not evaluated for canine safety. Additionally, human DES production has largely ceased. Your veterinarian must prescribe veterinary-appropriate DES through a compounding pharmacy if it is indicated for your dog.
How long does it take for DES to stop my dog's incontinence?
Most dogs show improvement within 5–7 days of starting the loading dose. If no improvement is seen after the full loading phase (5–7 days), your veterinarian may adjust the dose or consider an alternative diagnosis or treatment. Full continence on the maintenance dose may take 2–4 weeks to stabilize.
Is Incurin® (estriol) the same as DES?
No. Incurin® contains estriol, a naturally occurring, short-acting estrogen that is significantly weaker than DES. Estriol has a shorter half-life and lower receptor binding affinity, which translates to a wider safety margin — particularly regarding bone marrow suppression. Incurin® is FDA-approved specifically for canine USMI, whereas DES is used off-label through compounding pharmacies. Many veterinarians now consider Incurin® the preferred estrogen option for dogs that need hormonal therapy for incontinence.
Can male dogs take DES for incontinence?
DES is rarely used in male dogs. Male canine incontinence is less commonly related to estrogen deficiency and more often involves neurologic causes, prostate disease, or anatomical issues. Phenylpropanolamine (PPA) is the standard first-line medication for male dogs with urethral sphincter incompetence. Estrogen administration to male dogs also carries the risk of feminization effects, including mammary development and behavioral changes.
What should I do if I accidentally give my dog too much DES?
Contact your veterinarian or the ASPCA Animal Poison Control Center at (888) 426-4435 immediately (a consultation fee applies). Acute estrogen overdose in dogs can cause vomiting, lethargy, vulvar swelling, and — at sufficiently high doses — bone marrow suppression that may not become apparent for several days. Your vet will likely recommend baseline and follow-up CBC testing to monitor for delayed marrow effects. Do not wait for symptoms to appear before seeking guidance.
Are there natural or supplement alternatives to DES for incontinence?
Some supplements marketed for canine incontinence contain phytoestrogens (plant-derived estrogen-like compounds) such as soy isoflavones. However, there is limited peer-reviewed evidence supporting their efficacy for USMI, and phytoestrogens still interact with estrogen receptors — meaning they carry some of the same theoretical risks without the dosing precision of pharmaceutical products. Pumpkin seed extract has been studied in humans for overactive bladder but lacks robust canine-specific data. Always discuss supplements with your veterinarian before adding them, especially if your dog is already on medication.
Veterinary Disclaimer: This article provides educational information about diethylstilbestrol and canine incontinence management. It does not replace professional veterinary advice. Always consult your veterinarian before starting, stopping, or changing any medication for your dog. Your veterinarian will determine appropriate dosing, monitoring schedules, and whether DES is suitable for your individual dog's health profile. For further reading on hormonal therapies in veterinary medicine, refer to the Merck Veterinary Manual and discuss options with your veterinary care team.
Anouk Beaumont
All our authors care for dogs every day — read more of their work on the authors page.
